

CLAIMS LISTING

1. (previously presented) Pharmaceutical product for use in immunoreactions comprising at least part of tissues or cells of the male vegetal reproductive system, said at least part of tissues or cells comprising heterologous polypeptides as a result of the genetic modification of the plant which produces said tissues or cells.
2. (currently amended) Pharmaceutical product[[,]] according to claim 1, comprising whole/intact anthers or parts thereof.
3. (currently amended) Pharmaceutical product[[,]] according to claim 1, comprising whole pollen grains or parts thereof.
4. (withdrawn) Pharmaceutical product, according to claim 1, comprising at least part of polypeptides which are at least partially purified from said tissues and/or cells.
5. (currently amended) Pharmaceutical product[[,]] according to claim 1, wherein the polypeptide is selected from the group ~~that comprises at least part~~ consisting of eukaryotic antigens, prokaryotic antigens, viral antigens, ~~or~~ synthetic antigens, ~~as well as~~ therapeutic peptides, peptidic hormones, cytokines, interleucins, and combinations thereof.
6. (currently amended) Pharmaceutical product[[,]] according to claim 1, wherein said immunoreaction is the immunomodulation of ~~eucaryotes~~ eukaryotes.
7. (currently amended) Pharmaceutical product[[,]] according to claim 6, wherein said immunomodulation is ~~useful as an~~ immunotherapy.
8. (currently amended) Pharmaceutical product[[,]] according to claim 7, wherein said immunotherapy is ~~destined for the~~ treatment of allergies.
9. (currently amended) Pharmaceutical product[[,]] according to claim 7, wherein ~~the~~ said immunotherapy is ~~destined for the~~ treatment of autoimmune diseases.

10. (currently amended) Pharmaceutical product[[,]] according claim 7, wherein said immunotherapy is ~~destined for the~~ treatment of cancer.
11. (currently amended) Pharmaceutical product[[,]] according to claim 6, wherein said immunomodulation is ~~destined for the~~ vaccination of vertebrates.
12. (currently amended) Pharmaceutical product[[,]] according to claim 6, wherein said immunomodulation results from the parenteral administration to vertebrates.
13. (currently amended) Pharmaceutical product[[,]] according to claim 6, wherein said immunomodulation results from the administration into mucous surfaces of vertebrates.
14. (currently amended) Pharmaceutical product[[,]] according to claim 13, wherein said mucous surface is the nasal surface.
15. (currently amended) Pharmaceutical product[[,]] according to claim 13, wherein said mucous surface is the pulmonary surface.
16. (currently amended) Pharmaceutical product[[,]] according to claim 13, wherein said mucous surface is the oral or sublingual mucous surface.
17. (currently amended) Pharmaceutical product[[,]] according to claim 1, wherein said immunoreactions are *in vitro* immunoreactions.
18. (currently amended) Pharmaceutical product[[,]] according to claim 17, wherein said immunoreactions comprise cells which interact with said pharmaceutical product.
19. (currently amended) Pharmaceutical product[[,]] according to claim 17, wherein said immunoreactions comprise molecules which interact with said pharmaceutical product.
20. (currently amended) Pharmaceutical product[[,]] according to claim 19, wherein said molecules are antibodies or parts thereof.
21. (currently amended) Pharmaceutical product[[,]] according to claim 19, wherein said molecules are antigens or parts thereof.

22. (withdrawn) Production process of a pharmaceutical product for use in immunoreactions, comprising the step of cultivation of a genetically modified plant capable of originating tissues or cells of the male vegetal reproductive system comprising heterologous polypeptides.
23. (withdrawn) Process, according to claim 22, wherein said plant is modified with gene sequences comprising at least part of a promoter region functionally linked to a coding sequence of at least part of a heterologous polypeptide, so that said heterologous polypeptide is comprised in tissues or cells of the male vegetal reproductive system.
24. (withdrawn) Process, according to claim 23, wherein said promoter region comprises any nucleotide sequence capable of directing the expression of said heterologous polypeptide in anthers or in any subcellular localization of anthers.
25. (withdrawn) Process, according to claim 24, wherein said promoter region comprises any nucleotide sequence capable of directing the expression of said heterologous polypeptide in pollen grains cells.
26. (withdrawn) Process, according to claim 23, wherein said promoter region comprises any nucleotide sequence capable of directing the expression of said heterologous polypeptide in such a way as said heterologous polypeptide is present in mature pollen grains.
27. (withdrawn) Process, according to claim 26, wherein:
 - said promoter region comprises any nucleotide sequence capable of directing the gene expression in the anther's tapetum;
 - said sequence is functionally linked to the coding sequence of at least part of an oleosin-type protein; and
 - said sequence coding at least part of an oleosin-type protein is translationally fused to a sequence coding at least part of one or more polypeptides that are useful in immunoreactions.

28. (withdrawn) Process, according to claim 27, wherein said promoter region comprises at least part of the sequence SEQ. 2.
29. (withdrawn) Process, according to claim 27, wherein said sequence coding at least part of an oleosin-type protein comprises at least part of the sequence SEQ. 1.
30. (withdrawn) Process, according to claim 22, wherein said heterologous polypeptide is selected from the group that comprises at least part of peptides derived from eukaryotic organisms such as mammals including humans, plants, parasites, fungi or derived from procaryotic organisms such as bacteria or even viruses, and combinations thereof, regardless of being natural or synthetic peptides.
31. (new) A pharmaceutical product for vaccination of vertebrates comprising genetically modified pollen grains, comprising:
 - a) a promoter sequence of glycine-rich protein gene AtGRP17 of *A. thaliana*;
 - b) a coding sequence of a heterologous polypeptide; and
 - c) a heterologous polypeptide coded by said coding sequence.
32. (new) The pharmaceutical product according to claim 31, wherein said coding sequence of the heterologous polypeptide is fused to the coding sequence of an AtGRP17 gene product.
33. (new) The pharmaceutical product according to claim 1, wherein the heterologous polypeptide is selected from the group consisting of eukaryotic antigens, prokaryotic antigens, viral antigens, synthetic antigens, therapeutic peptides, peptidic hormones, cytokines, interleukins, and combinations thereof.